Nasdaq agrx.

PRINCETON, N.J., March 15, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX), a women's healthcare company, today announced that an abstract presenting data from two Phase 1 in ...

Nasdaq agrx. Things To Know About Nasdaq agrx.

Agile Therapeutics, Inc. (NASDAQ: AGRX), the commercial-stage women’s healthcare company, posted a 122% increase in third-quarter revenue year-over-year, driven by strong demand for Twirla&#9415 ...Nasdaq +78.81(+0.55%) Russell 2000 1,862.64 +53.62(+2.96%) Crude Oil 74.38 -1.58(-2.08%) Gold 2,091.70 +34.50(+1.68%) Advertisement Agile Therapeutics, Inc. (AGRX) NasdaqCM - NasdaqCM Real...PRINCETON, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be participating in ...Agile Therapeutics, Inc. Common Stock (AGRX) Historical Closing Prices - View free historical Nasdaq official closing price data at Nasdaq.com.We closed out the fourth quarter 2021 with a net loss of $23.4 million or $0.20 per share compared to the net loss of $17.6 million or $0.20 per share for the comparable period in 2020. The full ...

27 Feb 2023 ... PRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare ...Apr 28, 2023 · PRINCETON, N.J., April 28, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced preliminary expectations for first quarter 2023 Twirla ...

Agile Therapeutics Inc (NASDAQ:AGRX) shares are down by over 99% in the last year and down almost 72% in the last three months. As of this writing, Agile Therapeutics shares are trading at above $0.38 (52-week range of $0.37 to $50.40), giving it a market capitalization of more than $15 million.PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today reported financial results for the three and nine months ended ...

Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...Agile Therapeutics, Inc. (NASDAQ:AGRX) Q3 2023 Earnings Call Transcript November 9, 2023 Agile Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations were $-1.58.Agile Therapeutics, Inc. (NASDAQ:AGRX) announced its quarterly earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported …Based on analysts offering 12 month price targets for AGRX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Agile Thrpe stock price live 2.1400, this page displays NASDAQ AGRX stock exchange data. View the AGRX premarket stock price ahead of the market session or assess the after hours quote.

PRINCETON, NJ / ACCESSWIRE / November 22, 2023 / Agile Therapeutics, Inc. (NASDAQ:AGRX), the commercial-stage women's healthcare company, posted a 122% increase in third-quarter revenue year-over ...

Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm, along with recent purchases and sales information. Institutional ...

Dec 1, 2023 · According to the issued ratings of 2 analysts in the last year, the consensus rating for Agile Therapeutics stock is Buy based on the current 2 buy ratings for AGRX. The average twelve-month price prediction for Agile Therapeutics is $8.50 with a high price target of $12.00 and a low price target of $5.00. Learn more on AGRX's analyst rating ... AGRX Sales Forecast. Next quarter’s sales forecast for AGRX is $9.20M with a range of $9.20M to $9.20M. The previous quarter’s sales results were $6.66M. AGRX beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.22% of the time in the same period.AGRX Sales Forecast. Next quarter’s sales forecast for AGRX is $9.20M with a range of $9.20M to $9.20M. The previous quarter’s sales results were $6.66M. AGRX beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.22% of the time in the same period.Based on analysts offering 12 month price targets for AGRX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Dec 1, 2023 · Agile Therapeutics, Inc. (NASDAQ:AGRX) announced its earnings results on Tuesday, November, 2nd. The specialty pharmaceutical company reported ($7.20) EPS for the quarter, beating analysts' consensus estimates of ($7.60) by $0.40. The specialty pharmaceutical company earned $1.29 million during the quarter, compared to analysts' expectations of ... Nov 10, 2023 · 5 Cheap Pharmaceutical Stocks For 2022 Agile Therapeutics, Inc. (NASDAQ:AGRX) Q4 2022 Earnings Call Transcript. 5 Best Penny Stocks to Buy and Hold According to Reddit 10 Best Penny Stocks to Buy ... PRINCETON, N.J., April 22, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that the company has nominated Sharon ...

The latest price target for Agile Therapeutics ( NASDAQ: AGRX) was reported by Maxim Group on Friday, September 22, 2023. The analyst firm set a price target for 5.00 expecting AGRX to rise to ...PRINCETON, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three months ended September 30 ...Agile Therapeutics Stock (NASDAQ:AGRX), Quotes and News Summary · Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of ...Jun 27, 2017 · AGRX tried to move up and failed, broke the support level yesterday, and is now trading below it. Our idea is to take AGRX if it breaks the $ 1.97 price for further dec Hi traders, The consumer sector has been in a sharp decline in recent days and we have a trading idea in AGRX for further declines. AGRX tried to move up and failed, broke the ... Agile Therapeutics, Inc. (Agile or the Company) (NasdaqCM: NASDAQ: AGRX) is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Agile ...

PRINCETON, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the closing of its ...PRINCETON, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three months ended September 30 ...

AGRX U.S.: Nasdaq Agile Therapeutics Inc. Watch list NEW Set a price target alert Open Last Updated: Nov 15, 2023 10:21 a.m. EST Real time quote $ 2.2182 0.3182 16.75% Previous Close $1.9000...PRINCETON, N.J., July 18, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the appointment of Dennis P. Reilly as Chief Financial ...PRINCETON, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced the launch of I’m So Done, an ...PRINCETON, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be participating in ...Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm, along with recent purchases and sales information. Institutional ... The Company’s common stock will open for trading on the Nasdaq Market on Wednesday, April 27, 2022 on a split-adjusted basis under the current trading symbol "AGRX."PRINCETON, N.J., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced a partnership with Pandia Health, an online telehealth ...Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the granting of a previously disclosed inducement award to the...PRINCETON, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced the launch of I’m So Done, an ...

PRINCETON, N.J., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced a partnership with Pandia Health, an online telehealth ...

If you would like to register as a market maker in AGRX, contact Nasdaq Trading Operations at +1 212 231 5100. Email Alert Subscriptions: Nasdaq offers customers the ability to self select news delivery across various Nasdaq markets.

(NASDAQ: AGRX) Agile Therapeutics currently has 2,511,657 outstanding shares. With Agile Therapeutics stock trading at $2.13 per share, the total value of Agile ...PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today reported financial results for the three months ended June 30 ...Agile Therapeutics, Inc. (NASDAQ:AGRX) Q3 2023 Earnings Call Transcript November 9, 2023 Agile Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations were $-1.58.PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2023 financial results ...Find the latest Insider Activity data for Agile Therapeutics, Inc. Common Stock (AGRX) at Nasdaq.com.Feb 27, 2023 · PRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare company, today announced that it has received ... Agile Therapeutics Inc (NASDAQ: AGRX) expects Q2 FY22 Twirla demand to be at the mid-point of the earlier provided outlook of 20,000 - 22,000 cycles (new range 21,000 - 21,500 cycles). It ...Agile Therapeutics (NASDAQ: AGRX), a women's healthcare company, reported increasing Twirla prescription data for the first quarter 2022.Twirla cycles dispensed increased 29% to 16,602; Total ...Agile Therapeutics, Inc. Common Stock (AGRX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.

Real time Agile Therapeutics (AGRX) stock price quote, stock graph, news & analysis.PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today reported financial results for the three months ended June 30 ...Find the latest Earnings Report Date for Agile Therapeutics, Inc. Common Stock (AGRX) at Nasdaq.com.Agile Therapeutics Inc (NASDAQ:AGRX) is not the least popular stock in this group but hedge fund interest is still below average. Our overall hedge fund sentiment score for AGRX is 35.8.Instagram:https://instagram. sdyis blackrock a good investmentdollar tree stock dividendmarca real madrid Agile Therapeutics Inc (NASDAQ:AGRX) is the most popular stock in this table. On the other hand Clearfield, Inc. (NASDAQ: CLFD ) is the least popular one with only 3 bullish hedge fund positions. magnificent seven stocks etfshell plc share price Mar 21, 2023 · Follow. PRINCETON, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2022 ... Agile Therapeutics Inc Follow Share $2.06 Nov 27, 1:01:11 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Amarin Corporation plc $0.76 AMRN2.89% Apple Inc $190.63 AAPL0.34% Actinium... best automated crypto trading platform Find the latest Revenue & EPS data for Agile Therapeutics, Inc. Common Stock (AGRX) at Nasdaq.com.Agile Therapeutics, Inc. (NASDAQ:AGRX) announced its earnings results on Tuesday, November, 2nd. The specialty pharmaceutical company reported ($7.20) EPS for the quarter, beating analysts' consensus estimates of ($7.60) by $0.40. The specialty pharmaceutical company earned $1.29 million during the quarter, compared to analysts' expectations of ...